Description
What It Is
VA-2T is Vantage’s catalog name for tirzepatide, a synthetic dual agonist at the GLP-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). The compound is a 39-amino-acid peptide with fatty-acid conjugation for albumin binding, designed to activate both incretin receptors simultaneously. This dual mechanism is the subject of extensive preclinical research examining the additive or synergistic effects of combined GLP-1R and GIPR activation in metabolic tissue models.
Supplied lyophilized at 5mg per vial.
Who It’s For
Researchers in incretin receptor pharmacology, pancreatic islet biology, dual-agonist mechanism studies, and metabolic research models. The dual GLP-1R/GIPR profile makes it a useful tool compound for comparing single vs. dual incretin receptor activation in the same experimental system.
Key Research Applications
- Dual GLP-1R and GIPR co-activation and downstream signaling
- Comparative incretin pharmacology: mono-agonist vs. dual agonist
- Pancreatic beta-cell insulin secretion and islet biology
- GIP receptor biology and its interaction with the GLP-1 pathway
- Adipose tissue and hepatic metabolism in dual-incretin receptor models
Handling & Reconstitution
Store lyophilized VA-2T (tirzepatide) at 2 to 8°C, protected from light and moisture. Reconstitute with a suitable sterile solvent. The compound is water-soluble. Once reconstituted, store at 4°C and use within 28 days. Aliquot to avoid repeated freeze-thaw cycles.
Disclaimer: For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
Full reference record, including verified molecular data and the batch COA policy: Tirzepatide.
Reviews
There are no reviews yet.